Health spending in the United States has always been a topic of great concern. It is an issue that affects individuals, families, and the entire nation. In 2022, health spending in the U.S. rose by 4.1%, reaching a staggering $4.5 trillion. While this increase is lower than the 10.6% growth seen in 2020, it is
Health
The healthcare industry is on the brink of a revolutionary change. Five healthcare companies have taken a significant step towards establishing a nationwide network for exchanging patient health information. This groundbreaking development has the potential to shape the future of healthcare as we know it. During an event held at the headquarters of the U.S.
Axatilimab, an investigational monoclonal antibody, has demonstrated promising results in the treatment of recurrent/refractory chronic graft-versus-host disease (cGVHD), according to findings from the phase II AGAVE-201 trial. These results, presented at the American Society of Hematology annual meeting by Daniel Wolff, MD, PhD, indicate that axatilimab achieved rapid and durable responses in patients with cGVHD.
Autologous stem-cell transplantation (ASCT) has emerged as a more effective treatment option compared to CAR T-cell therapy for patients with relapsed large B-cell lymphoma (LBCL) in complete remission, according to a retrospective analysis. The study, presented at the American Society of Hematology (ASH) meeting, demonstrated that ASCT was associated with significantly fewer relapses at 2
Breast cancer remains a significant health concern for women globally, and advancements in treatment options have led to more personalized approaches based on individual patient characteristics. One such approach is the use of bilateral mastectomy, particularly in women with a pathogenic BRCA1 variant. However, a recent international analysis has questioned the survival benefits of this
A recent phase II trial, KEYLYNK-009, explored the efficacy of a maintenance strategy involving a checkpoint blockade and a PARP inhibitor for patients with triple-negative breast cancer (TNBC). Unfortunately, the results indicated that this approach did not improve survival outcomes for unselected patients with TNBC. Despite the disappointing findings, the trial did demonstrate a good
A recent randomized trial has revealed that low-dose naltrexone does not provide any additional pain relief compared to a placebo in patients with fibromyalgia. This is a significant setback for the hopes that this opioid receptor antagonist could be an effective treatment for a condition that has thus far been difficult to manage. The trial,
In a recent study presented at the annual meeting of the International Gynecologic Cancer Society, the antibody-drug conjugate trastuzumab deruxtecan (T-DXd; Enhertu) has shown promising response rates in heavily pretreated patients with HER2-expressing gynecologic cancers. Dr. Ritu Salani from the University of California Los Angeles highlights the significance of trastuzumab deruxtecan in the field of
Serial infusions have emerged as a potential solution in restoring amniotic fluid lost due to the lack of fetal renal development before 26 weeks’ gestation. This groundbreaking approach has significantly improved the rate of live births among cases of fetal bilateral renal agenesis, a condition that is otherwise uniformly lethal. The RAFT trial, which investigated
Myelodysplastic syndromes (MDS) pose a significant challenge in clinical management, particularly for patients with lower-risk disease who relapse or have refractory disease. The IMerge trial investigated the efficacy of imetelstat, a first-in-class telomerase inhibitor, in achieving red blood cell (RBC) transfusion independence in this patient population. The IMerge trial, led by Dr. Uwe Platzbecker and